129378-52-5

Basic information

• Product Name: 2-[tert-butyl(dimethyl)silyl]-N,N-dimethyl-1H-imidazole-1-sulfonamide
• CAS NO: 129378-52-5
• Molecular Formula: C₁₁H₂₃N₃O₂SSi
• Molecular Weight: 289.4697
• Mol File: 129378-52-5.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 355.7°C at 760 mmHg
• Flash Point: 168.9°C
• Density: 1.08g/cm³
• Vapor Pressure: 3.07E-05mmHg at 25°C
• Refractive Index: 1.511
• CAS DataBase Reference: 2-[tert-butyl(dimethyl)silyl]-N,N-dimethyl-1H-imidazole-1-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[tert-butyl(dimethyl)silyl]-N,N-dimethyl-1H-imidazole-1-sulfonamide(129378-52-5)
• EPA Substance Registry System: 2-[tert-butyl(dimethyl)silyl]-N,N-dimethyl-1H-imidazole-1-sulfonamide(129378-52-5)

Safety Data

• Hazardous Substances Data: 129378-52-5(Hazardous Substances Data)

Usage

General Description

2-[tert-butyl(dimethyl)silyl]-N,N-dimethyl-1H-imidazole-1-sulfonamide is a chemical compound with a complex structure. It contains a tert-butyl group and two dimethylsilyl groups attached to an imidazole ring, as well as a sulfonamide functional group. It is a highly specific and potent inhibitor of the enzyme carbonic anhydrase, which is involved in the regulation of pH in various tissues and organs in the body. The compound has potential applications in the treatment of conditions such as glaucoma, epilepsy, and cancer, and its unique structure makes it an interesting target for medicinal chemistry research.

Upstream product

• 10297-05-9 1-chloro 4-iodobutane 
• 78162-58-0 N,N-dimethyl-1H-imidazole-1-sulfonamide 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 6940-76-7 1-iodo-3-chloro-propane 
• 60274-60-4 1-chloro-5-iodopentane 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 5927-18-4 trimethyl phosphonoacetate 
• 109-72-8 n-butyllithium 
• 288-32-4 1H-imidazole 
• 13360-57-1 dimethylamino sulfonyl chloride 

Downstream Products

• 169221-19-6 2-(tert-butyldimethylsilyl)-5-(2-deoxy-3,5-di-O-benzyl-D-ribosyl)-N,N-dimethylimidazole-1-sulfonamide 
• 169139-35-9 2-(tert-butyldimethylsilyl)-5-(2-deoxy-3,5-di-O-benzyl-D-ribosyl)-N,N-dimethylimidazole-1-sulfonamide 
• 304891-33-6 (10S)-2-tert-butyldimethylsilyl-5-(2',3',5'-tri-O-benzyl-L-arabinosyl)-N,N-dimethylimidazole-1-sulfonamide 
• 304891-24-5 (10R)-2-tert-butyldimethylsilyl-5-(2',3',5'-tri-O-benzyl-L-arabinosyl)-N,N-dimethylimidazole-1-sulfonamide 
• 340699-29-8 5-[(1S,2S)-2-Benzyloxy-2-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-1-hydroxy-ethyl]-2-(tert-butyl-dimethyl-silanyl)-imidazole-1-sulfonic acid dimethylamide 
• 340699-17-4 5-[(1R,2R)-2-Benzyloxy-2-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-1-hydroxy-ethyl]-2-(tert-butyl-dimethyl-silanyl)-imidazole-1-sulfonic acid dimethylamide 
• 351011-92-2 2-tert-butyldimethylsilyl-5-[(1'R,3'S)-3'-dibenzylamino-1',4'-dihydroxybutyl]-N,N-dimethylimidazole-1-sulfonamide 
• 351011-93-3 2-tert-butyldimethylsilyl-5-[(1'R,3'S)-3'-dibenzylamino-1',4'-dihydroxybutyl]-N,N-dimethylimidazole-1-sulfonamide 
• 425641-98-1 5-[(1S,2S)-2-Benzyloxy-2-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-1-hydroxy-ethyl]-2-(tert-butyl-dimethyl-silanyl)-imidazole-1-sulfonic acid dimethylamide 
• 426824-56-8 5-[(S)-((3aR,5R,6S,6aR)-6-Benzyloxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-hydroxy-methyl]-2-(tert-butyl-dimethyl-silanyl)-imidazole-1-sulfonic acid dimethylamide 
• 426824-57-9 5-[(R)-((3aR,5R,6S,6aR)-6-Benzyloxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-hydroxy-methyl]-2-(tert-butyl-dimethyl-silanyl)-imidazole-1-sulfonic acid dimethylamide 
• 571167-74-3 5-[(1RS,4S)-5-benzyloxy-1,4-dihydroxypentyl]-2-(tert-butyldimethylsilyl)-N,N-dimethyl-1H-imidazolesulfonamide 
• 952024-27-0 N,N-dimethyl-5-(4-benzyloxy-1-hydroxybutyl)-2-(tert-butyldimethylsilanyl)imidazole-1-sulphonamide 
• 1126428-37-2 5-(4-tert-butylbenzoyl)-2-(tert-butyldimethylsilyl)-N,N-dimethyl-1H-imidazole-1-sulfonamide 

Relevant articles and documents

From histamine to imidazolylalkyl-sulfonamides: The design of a novel series of histamine H3-receptor antagonists

Histamine was converted to a selective histamine H3-receptor antagonist by capping the primary amine with 2-naphthalenesulfonyl chloride. Higher receptor affinity and lower variability in the data from the various bioassays were achieved with the 2-naphthalensulfonamides of histamine homologues.

Homologs of Histamine as Histamine H3 Receptor Antagonists: A New Potent and Selective H3 Antagonist, 4(5)-(5-Aminopentyl)-1H-imidazole

The influence of alkyl chain length variation on the histamine H3 receptor activity of histamine homologs 1 was investigated.A series of 4(5)-(ω-aminoalkyl)-1H-imidazoles 1 was prepared with an alkyl chain length varying from one methylene group to 10 methylene groups.Besides the H3 activity, the affinities of these compounds for the H1 and H2 receptors were determined.The ethylene chain of histamine is optimal for agonistic activity on all three histamine receptor subtypes.For the H3 receptor, elongation of the alkyl chain from three methylene groups on leads to compounds with antagonistic properties. 4(5)-(5-Aminopentyl)-1H-imidazole (impentamine, 1e) is the most potent and selective H3 antagonist from this series of 4(5)-(ω-aminoalkyl)-1H-imidazoles 1, with a pA2 value of 8.4 (on guinea pig jejunum).A specific antagonistic binding site for this compound is proposed.

Novel structural analogs of glyphosate based on azoles. 1. Synthesis of 1H-imidazoles containing carboxyl and phosphoryl groups in the ring

A general method has been developed for the synthesis of 1H-imidazoles containing a phosphoryl group in positions 2 or 4(5) based on lithium intermediates. The possibility of further functionalization of the ring using electrophiles has also been demonstrated.

4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same

The compound of the formula wherein the * indicates an asymmetric carbon, is specific to alpha2B adrenergic receptors in preference over alpha2A and alpha2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors.